Fewer adverse events leading to dose interruptions or reductions ( 25 [ 32 % ] of 79 patients vs 90 [ 60 % ] of 150 ) or treatment discontinuation ( 17 [ 22 % ] vs 54 [ 36 % ] ) occurred in patients in the 200 mg group than in the 800 mg group .